Role of p53 in the responses of human urothelial cells to genotoxic damage

被引:10
作者
Diggle, CP
Pitt, E
Harnden, P
Trejdosiewicz, LK
Southgate, J [1 ]
机构
[1] Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5YW, N Yorkshire, England
[2] Imperial Canc Res Fund, Canc Med Res Unit, Leeds, W Yorkshire, England
[3] St James Univ Hosp, Dept Pathol, Leeds, W Yorkshire, England
关键词
p53; urothelium; bladder cancer; mitomycin C; gamma-radiation;
D O I
10.1002/ijc.1331
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of p53 function is a feature of many types of malignancy, including transitional-cell carcinoma (TCC), where it is associated with high-grade lesions and the development of muscle-invasive disease. Genotoxic: agents used as part of the treatment strategy may contribute to tumour progression by inducing further non-lethal DNA damage in surviving cells. To determine the role of p53 in cellular responses to genotoxic agents, we used cultured normal human urothelial (NHU) cells and NHU cells with disabled p53 function. Mitomycin C and gamma -radiation caused normal cells to undergo an extended period of cell-cycle arrest, followed by complete recovery of proliferative potential. In contrast, cells with disabled p53 function, whether karyotypically normal (HU-EB cells) or post-crisis with karyotypic abnormalities (HU-E6P cells), underwent extensive apoptosis. Overall survival was dose-dependent, and surviving HU-E6 cells from low-dose treatments showed clonal karyotypic abnormalities. These findings demonstrate that p53 status is a crucial factor in determining the ability of urothelial cells to survive DNA damage and suggest caution in the use of genotoxic treatments for low-grade tumours as our data imply that malignancies that have not yet lost p53 function will show the same "repair-and-recovery" response as normal cells. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 23 条
[1]   Role of p53 mutations in the radiosensitivity status of tumor cells [J].
Chiarugi, V ;
Magnelli, L ;
Cinelli, M .
TUMORI, 1998, 84 (05) :517-520
[2]  
Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0
[3]   p53: Biology and role for cellular radiosensitivity [J].
Dahm-Daphi, J .
STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (06) :278-285
[4]  
Diggle CP, 2000, J LIPID RES, V41, P1509
[5]   p53 tumor suppressor gene: From the basic research laboratory to the clinic - An abridged historical perspective [J].
Harris, CC .
CARCINOGENESIS, 1996, 17 (06) :1187-1198
[6]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[7]   UROTHELIAL TISSUE-CULTURE FOR BLADDER RECONSTRUCTION - AN EXPERIMENTAL-STUDY [J].
HUTTON, KAR ;
TREJDOSIEWICZ, LK ;
THOMAS, DFM ;
SOUTHGATE, J .
JOURNAL OF UROLOGY, 1993, 150 (02) :721-725
[8]  
JAHNSON S, 1995, EUR UROL, V28, P135
[9]   Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer [J].
Koga, F ;
Kitahara, S ;
Arai, K ;
Honda, M ;
Sumi, S ;
Yoshida, K .
JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (04) :416-423
[10]   CANCER - P53, GUARDIAN OF THE GENOME [J].
LANE, DP .
NATURE, 1992, 358 (6381) :15-16